This includes: Malignant pleural mesothelioma: Keytruda is prescribed to adults as a first-choice treatment for malignant pleural mesothelioma that’s advanced or has spread to other parts of the ...

It's currently under consideration as a first-line treatment for advanced or metastatic malignant pleural mesothelioma, among ...

It's currently under consideration as a first-line treatment for advanced or metastatic malignant pleural mesothelioma, among other indications. So, at least for now, it is likely that Keytruda ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Novocure has an additional Phase 3 test underway evaluating Optune Lua and the Merck checkpoint inhibitor Keytruda as a first ... for malignant pleural mesothelioma, a cancer affecting the lining ...

Meanwhile, rival PD-1 inhibitor Keytruda (pembrolizumab) from Merck & Co/MSD was granted accelerated FDA approval as a second-line treatment for HCC after frontline therapy with Nexavar in 2018 ...

The company has brought the antibody to market ahead of Merck's favezelimab, which is being developed as a combination with PD-1 inhibitor Keytruda ... and mesothelioma. It's worth noting also ...

Keytruda and Opdivo may treat cancers that are still growing ... Immunotherapy for malignant mesothelioma. Putzu C, Canova S, Paliogiannis P, et al. Duration of Immunotherapy in Non-Small Cell Lung ...

Novocure’s device first won FDA approval in 2011 in glioblastoma, a rapid and usually deadly type of brain cancer, and then scored another nod in 2019 for the lung cancer mesothelioma ... drugs like ...